Anxiety disorders: use of benzodiazepines

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Anxiety disorders are the most common type of mental illness. Due to their high prevalence (3.3% of the global disease burden), chronic course and a large number of comorbidities, anxiety disorders are among the nine leading causes of disability. The presence of anxiety in heart disease, cancer or lung disease negatively affects the quality of life, treatment adherence, prognosis and treatment costs. Anxiety disorders are treated using psychotherapy, pharmacotherapy or a combination of both. Benzodiazepines are an effective treatment for anxiety, if prescribed as directed and with control over adverse events, some of which are described in the article. Unlike SSRIs, which are first-line drugs for treating anxiety disorders, the anxiolytic effect of which develops only after 2–4 weeks of use, benzodiazepines provide a rapid pharmacological response with reduction of anxiety symptoms within a short time. In this regard, their use is advisable in short courses for rapid symptom relief. Diamidazepam, a member of the benzodiazepine group, combines a powerful anti-anxiety effect with an activating and anti-asthenic effect, while being virtually devoid of the side effects of classic benzodiazepines in the form of excessive sedation, drowsiness, and muscle relaxation.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Olga Kotova

People’s Friendship University of Russia (RUDN University); International Society “Stress under Control”

Хат алмасуға жауапты Автор.
Email: ol_kotova@mail.ru
ORCID iD: 0000-0002-3908-0381

Cand. Sci. (Med.), Neurologist, Psychiatrist, Associate Professor at the Department of Psychiatry, Psychotherapy and Psychosomatic Pathology, Faculty of Continuous Medical Education, Medical Institute, People’s Friendship University of Russia (RUDN University); Vice-President of the International Society “Stress Under Control”

Ресей, Moscow; Moscow

Elena Akarachkova

International Society “Stress under Control”; Rehaline Rehabilitation Center

Email: ol_kotova@mail.ru
ORCID iD: 0000-0002-7629-3773

Dr. Sci. (Med.), Neurologist, President of the International Society “Stress Under Control”; Deputy Chief Physician of the Rehaline Rehabilitation Center

Ресей, Moscow; Krasnogorsk

Aleksandra Belyaeva

People’s Friendship University of Russia (RUDN University)

Email: ol_kotova@mail.ru
ORCID iD: 0009-0002-1047-7788

Student, Faculty of Continuous Medical Education, Medical Institute

Ресей, Moscow

Dzhinna Lebedeva

Regional Treatment and Rehabilitation Center; Tyumen State Medical University

Email: ol_kotova@mail.ru

Dr. Sci. (Med.), neurologist, Honored Doctor of the Russian Federation, Chief Physician, Regional Treatment and Rehabilitation Center; Associate Professor of the Department of Medical Prevention and Rehabilitation, Institute of Public Health and Digital Medicine, Tyumen State Medical University

Ресей, Tyumen; Tyumen

Әдебиет тізімі

  1. Vos T., Abajobir A.A., Abbafati C., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211–1259. https://dx.doi.org/10.1016/S0140-6736(17)32154-2
  2. Kroenke K., Hirschtritt M.E. Walking the Benzodiazepine High Wire. Psychiatr Serv. 2023;74(1):73–75. https://dx.doi.org/10.1176/appi.ps.202100671
  3. Shepardson R.L., Buchholz L.J., Weisberg R.B., Funderburk J.S. Psychological interventions for anxiety in adult primary care patients: a review and recommendations for future research. J Anxiety Disord. 2018;54:71–86. https://dx.doi.org/10.1016/j.janxdis.2017.12.004
  4. Котова О.В., Беляев А.А., Акарачкова Е.С. Современные методы диагностики и лечения тревожных и депрессивных расстройств. Русский медицинский журнал. Медицинское обозрение. 2021;5(10):648–653. [Kotova O.V., Belyaev A.A., Akarachkova E.S. Modern methods of diagnosis and treatment of anxiety and depressive disorders. Russian medical journal. Medical Review. 2021;5(10):648–653. (In Russ.)]. https://dx.doi.org/10.32364/2587-6821-2021-5-10-648-653
  5. Penninx B.W., Pine D.S., Holmes E.A., Reif A. Anxiety disorders. Lancet. 2021;397(10277):914–927. https://dx.doi.org/10.1016/S0140-6736(21)00359-7
  6. Alonso J., Liu Z., Evans-Lacko S., et al. Treatment gap for anxiety disorders is global: results of the World Mental Health Surveys in 21 countries. Depress Anxiety 2018;35:195–208. https://dx.doi.org/10.1002/da.22711
  7. Regier D.A., Narrow W.E., Rae D.S., et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50(2):85–94. https://dx.doi.org/10.1001/archpsyc.1993.01820140007001
  8. Alonso J., Lepine J.P. ESEMeD/MHEDEA 2000 Scientific Committee. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry. 2007;68(suppl 2):3–9. https://dx.doi.org/10.1002/da.22711
  9. Smolders M., Laurant M., Verhaak P., et al Adherence to evidence-based guidelines for depression and anxiety disorders is associated with recording of the diagnosis. Gen Hosp Psychiatry. 2009;31(5):460–469. https://dx.doi.org/10.1016/j.genhosppsych.2009.05.011
  10. Акарачкова Е.С., Кадырова Л.Р., Климов Л.В., и др. На приеме – тревожный пациент. Consilium Medicum. 2024;26(2):125–130. [Akarachkova E.S., Kadyrova L.R., Klimov L.V., et al. An anxious patient at the reception. Consilium Medicum. 2024;26(2):125–130. (In Russ.)]. https://dx.doi.org/10.26442/20751753.2024.2.202672
  11. Bandelow B., Michaelis S., Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107. https://dx.doi.org/10.31887/DCNS.2017.19.2/bbandelow
  12. Gale C., Glue P., Guaiana G., et al. Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorder: systematic review and meta-analysis. J Psychopharmacol. 2019;33:543–547. https://dx.doi.org/10.1177/0269881118822146
  13. Breilmann J., Girlanda F., Guaiana G., et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2019;3(3):CD010677. https://dx.doi.org/10.1002/14651858.CD010677.pub2
  14. Gupta A., Bhattacharya G., Farheen S.A., et al: Systematic review of benzodiazepines for anxiety disorders in late life. Ann Clin Psychiatry. 2020;32:114–127.
  15. Shinfuku M., Kishimoto T., Uchida H., et al. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2019;34(5):211–221. https://dx.doi.org/10.1097/YIC.0000000000000276
  16. Osler M., Jorgensen M.B. Associations of benzodiazepines, Z-drugs, and other anxiolytics with subsequent dementia in patients with affective disorders: a nationwide cohort and nested case-control study. Am J Psychiatry 2020;177:497–505. https://dx.doi.org/10.1176/appi.ajp.2019.19030315
  17. Gulpers B., Ramakers I., Hamel R., et al. Anxiety as a predictor for cognitive decline and dementia: a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2016;24:823–842. https://dx.doi.org/10.1016/j.jagp.2016.05.015
  18. Nader D., Gowing L. Is long-term benzodiazepine use a risk factor for cognitive decline? Results of a systematic review. J Addict. 2020;2020:1569456. https://dx.doi.org/10.1155/2020/1569456
  19. Seppala L.J., van de Glind E.M.M., Daams J.G., et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: III. Others. J Am Med Dir Assoc. 2018;19(4):372.e1–372.e8. https://dx.doi.org/10.1016/j.jamda.2017.12.099
  20. Maust D.T., Lin L.A., Blow F.C. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97–106. https://dx.doi.org/10.1176/appi.ps.201800321
  21. Votaw V.R., Geyer R., Rieselbach M.M., et al. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95–114. https://dx.doi.org/10.1016/j.drugalcdep.2019.02.033
  22. Sakurai H., Takeshima M., Inada K., et al. Clinical practice for unspecified anxiety disorder in primary care. PCN Rep. 2023;2(3):e118. https://dx.doi.org/10.1002/pcn5.118
  23. Hirschtritt M.E., Olfson M., Kroenke K. Balancing the risks and benefits of benzodiazepines. JAMA. 2021;325(4):347–348. https://dx.doi.org/10.1001/jama.2020.22106
  24. Kroenke K., Hirschtritt M.E. Walking the benzodiazepine high wire. Psychiatr Serv. 2023;74(1):73–75. https://dx.doi.org/10.1176/appi.ps.202100671
  25. Бурчинский С.Г. Роль и место бензодиазепинов в фармакотерапии посттравматического стрессового расстройства. Международный неврологический журнал. 2018;4(98):68–74. [Burchinsky S.G. Role and place of benzodiazepines in pharmacotherapy of posttraumatic stress disorder. International Neurological Journal. 2018;98(4):68–74. (In Russ.)]. https://dx.doi.org/10.22141/2224-0713.4.98.2018.139428
  26. Korkhov V.M., Tkachuk N.A., Makan S.Y., et al. Affinities of gidazepam and its analogs for mitochondrial benzodiazepine receptors. J Recept Signal Transduct Res. 2002;22(1–4):411–420. https://dx.doi.org/10.1081/rrs-120014610
  27. Баскаков Е.В., Григорьев А.В., Глобенко А.А., и др. Изучение фармакокинетического профиля лекарственного препарата Гидазепам®, таблетки, 50 мг в исследовании биоэквивалентности. Фармакокинетика и фармакодинамика. 2023;(3):94–103. [Baskakov E.V., Grigoriev A.V., Globenko A.A., et al. Study of the pharmacokinetic profile of the drug Gidazepam®, tablets, 50 mg in a bioequivalence study. Pharmacokinetics and pharmacodynamics. 2023;(3):94–103. (In Russ.)]. https://doi.org/10.37489/2587-7836-2023-3-94-103
  28. Andronati S.A., Zin’kovskii V.G., Totrova M.Iu., et al. Biokinetics of a new prodrug gidazepam and its metabolite. Biull Eksp Biol Med. 1992;113(1):45–47. (In Russ.)].

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2025